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ABSTRACT Surfactant protein B (SP-B) is a 17-kDa dimeric protein produced by alveolar type II cells. Its main function is
to lower the surface tension by inserting lipids into the air/liquid interface of the lung. SP-B’s function can be mimicked by
a 25-amino acid peptide, SP-B1–25, which is based on the N-terminal sequence of SP-B. We synthesized a dimeric version
of this peptide, dSP-B1–25, and the two peptides were tested for their surface activity. Both SP-B1–25 and dSP-B1–25 showed
good lipid mixing and adsorption activities. The dimeric peptide showed activity comparable to that of native SP-B in the
pressure-driven captive bubble surfactometer. Spread surface films led to stable near-zero minimum surface tensions during
cycling while protein free, and films containing SP-B1–25 lost material from the interface during compression. We propose that
dimerization of the peptide is required to create a lipid reservoir attached to the monolayer from which new material can enter
the surface film upon expansion of the air/liquid interface. The dimeric state of SP-B can fulfill the same function in vivo.
INTRODUCTION
Pulmonary surfactant is a mixture of lipids and specific
proteins that is secreted into the alveolar fluid by alveolar
type II cells. Its main function is to reduce the surface
tension at the air/liquid interface in the lung. This is
achieved by forming a surface film that consists of a mono-
layer that is highly enriched in dipalmitoylphosphatidylcho-
line (DPPC) and bilayer lipid/protein structures closely at-
tached to it. This surface film reduces the work of breathing
and prevents alveolar collapse upon end expiration. The in
vivo existence of such a film has recently been confirmed
by electron microscopy (Schu¨rch et al., 1995).
The highly hydrophobic surfactant-specific proteins B
and C (SP-B and SP-C) are required for a rapid insertion of
new material from the lipid bilayer structures to the mono-
layer upon inspiration. In addition to reducing the work
required for breathing, this prevents serum components
from entering the surface film. These serum components, of
which albumin is the most abundant, disturb surfactant
function, and an increase in these serum components in the
bronchoalveolar lavage is often observed in several diseases
related to surfactant dysfunction (Byrne et al., 1992; Hall-
man et al., 1989; Jorens et al., 1992; Matsumoto et al., 1992;
Nakos et al., 1997). SP-B and SP-C are also likely involved
in the DPPC enrichment of the monolayer (for a review see
Pe´rez-Gil and Keough, 1998). A monolayer enrichment of
DPPC is required to create stable surface films with near-
zero surface tensions.
SP-B is a 17 kDa homodimer. Secondary structure
analysis and homology with related proteins, especially
members of the saposin-like family (Patthy, 1991), predict
an SP-B structure that contains four amphipathic -helices
(Andersson et al., 1995). These helices are thought to in-
teract with the surfactant lipids, with a specific interaction
between anionic lipids and the positive charges of SP-B
(Baatz et al., 1990; Longo et al., 1993). The structure of
SP-C, a 4.2-kDa protein containing 35 amino acids, has
been completely resolved in solution and micelles by NMR
(Johansson et al., 1994). Its main characteristics are a poly-
valyl -helix that can exactly span a lipid bilayer and a tail
that contains two palmitoylated cysteines.
The importance of SP-B in surfactant is apparent from the
lethal respiratory distress that is caused by SP-B deficiency
in humans (Nogee et al., 1994) and in SP-B knock-out mice
(Tokieda et al., 1997). A lowered or total lack of all sur-
factant components, due to immaturity of the lungs in pre-
mature infants or inflammation or trauma in adults, leads to
respiratory distress syndrome (RDS). Administration of ex-
ogenous surfactant has been proven a successful strategy for
treating the neonatal form of RDS, and improvements are
observed in ARDS as well (for a review see Robertson and
Halliday, 1998). However, human surfactant is scarce, and
therefore replacement surfactants are derived from animals.
The disadvantage of this is that immunological responses
and viral infections of the treated patient might occur. A
completely synthetic surfactant might overcome these prob-
lems, and a major research area has evolved in this direction.
The development of a purely synthetic surfactant requires
a thorough understanding of the role of the protein and lipid
components in pulmonary surfactant. Several peptides
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based on either SP-B or SP-C have been tested (Bruni et al.,
1991, 1998; Johansson et al., 1995; Nilsson et al., 1998;
Takei et al., 1996). SP-B1–25 is a peptide based on the
N-terminal segment of human SP-B (hSP-B) and has been
shown to have an amphipathic helical structure (Gordon et
al., 1996). It has a high affinity for phospholipid monolayers
and increases the collapse pressure of palmitic acid (PA)
monolayers (Lipp et al., 1996; Waring et al., 1989). The
peptide also permits resistance to the inhibitory effect of
plasma constituents that inhibit surfactant and partly re-
stores lung compliance in two animal models (Bruni et al.,
1998). All of these activities are known characteristics of
native SP-B. To mimic the dimeric state of native SP-B we
synthesized the new peptide dSP-B1–25. The monomers of
this dimer differ from the previously mentioned SP-B1–25 in
that a cysteine at position 11 was substituted by alanine,
leaving only one cysteine in the peptide. A disulfide linkage
between two cysteines of the monomers results in a dimer of
the SP-B1–25 peptide (Fig. 1). The activity of both peptides
was tested in vitro, using the captive bubble surfactometer
(CBS) and lipid mixing experiments. Both peptides show
good activity in several aspects of surface film formation
and dynamics, with a clear positive effect of the dimerization
on the respreadability of lipids under dynamic conditions.
EXPERIMENTAL PROCEDURES
Materials
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1-palmitoyl-2-
oleoyl-sn-glycero-3-phospho-rac-(1-glycerol) (POPG) were obtained from
Avanti Polar Lipids (Alabaster, AL); 1-palmitoyl-2-(1-pyrenedecanoyl)-
sn-glycero-3-phosphocholine (pyrene-PC) was from Molecular Probes;
HEPES was from Life Technologies (Paisley, Scotland); EDTA, calcium
chloride (CaCl2), chloroform (CHCl3), and methanol (MeOH) were from
Baker Chemicals B.V. (Deventer, the Netherlands). Organic solvents were
distilled before use. hSP-B and hSP-C were isolated from amniotic fluid,
using protocols normally used for lung lavage, as described previously
(Oosterlaken Dijksterhuis et al., 1991).
Peptide synthesis
Molecular design rational
Using the known residue-specific secondary structure of SP-B1–25 (Gordon
et al., 2000) (Fig. 2), we made modifications in the amino acid sequence to
make it more closely emulate the structure and function of the native
protein. Cys11 was replaced with Ala to provide a single disulfide link at
the N-terminal helical residue Cys8, allowing the formation of a unique
C11A SP-B1–25 homodimer. This dimeric peptide will be referred to as
dSP-B1–25.
Solid-phase peptide synthesis, purification, and
characterization of SP-B1–25 and dSP-B1–25
The SP-B1–25 peptide and dSP-B1–25 monomer (C11A SP-B1–25) were
synthesized on a 0.25-mmol scale with an Applied Biosystems model 431A
peptide synthesizer, using a FastMoc strategy (Fields et al., 1991). The
peptides were synthesized with prederivatized Fmoc-Gly resin (Calbio-
chem-Nova, La Jolla, CA) or PEG-PA resin (Perceptive Biosystems, Old
Connecticut Path, MA) and were single-coupled for all residues.
Crude peptide product was purified by reverse-phase high performance
liquid chromatography with a Vydac reverse-phase C8-column (Vydac,
Hesperia, CA), using a linear gradient of water:acetonitrile (0–100%
acetonitrile with 0.1% trifluoroacetate as an anion pairing agent) over a
period of 1 h. Purified peptide was freeze-dried twice at a concentration of
5 mg peptide/ml from acetonitrile:10 mM HCl solutions to remove acetate
counterions that interfere with dimerization and in vivo or in vitro mea-
surements. The molecular mass of the monomeric SP-B1–25 peptides was
confirmed by fast atom bombardment mass spectroscopy or electrospray
mass spectroscopy. Masses of 2926.7 and 2895.5 Da were observed for
SP-B1–25 and C11A SP-B1–25, respectively, which correlates well with the
calculated masses.
For the formation of the dimer peptide, C11A SP-B1–25 monomer was
first reduced with 100 mM dithiothreitol (DTT) in trifluoroethanol
(TFE):10 mM sodium phosphate buffer pH 7.5 (1:1, v/v) at a concentration
of 1 mg peptide/ml solution for 12 h before oxidation. The peptide solution
was then passed through a Sephadex P-10 size exclusion column using
TFE:10 mM sodium phosphate buffer (pH 7.5) (1:1, v/v) to remove the
reducing agent before oxidation-disulfide formation. The isolated peptide
solution was then freeze-dried overnight to remove solvent. The dry
peptide powder was dissolved in TFE:10 mM sodium phosphate buffer (pH
7.5) (1:1, v/v) at a concentration of 1–2 mg peptide/ml and stirred vigor-
ously for 24 h to facilitate the air-mediated oxidation of the peptide
monomers to form a disulfide-linked homodimer dSP-B1–25 (preferred
method of dimer formation). The molecular mass of the peptide was
confirmed by electrospray mass spectroscopy and indicated the yield of
dimeric product to be essentially 100%. The mass spectrum shows five
FIGURE 1 The sequence of SP-B1–25 and dSP-B1–25 in one-letter code.
FIGURE 2 The amino acid sequence and specific secondary structure of
SP-B1–25 in surfactant lipid (Gordon et al., 2000; Protein Data Bank ID:
1DFW). Residue specific secondary assignments are as follows: h, helix; e,
extended; s, bend; _, disordered.
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major peaks with masses of 579.8, 725.0, 828.1, 966.2, and 1159.4 Da,
which all arise from the peptide (the 10, 8, 7, 6, and 5 ions, respectively)
with an observed average mass of 5790.8 Da. This is very close to the
calculated mass of 5791.2 Da. The concentrations of peptides and native
surfactant proteins for control experiments were determined by quantitative
amino acid analysis (UCLA Microsequencing Facility, Los Angeles, CA,
and Eurosequence bv, Groningen, the Netherlands).
Vesicle preparation
Small unilamellar vesicles (SUVs) for lipid mixing and captive bubble
surfactometer experiments were prepared as follows. Lipids from stock
solutions in CHCl3/MeOH with or without peptides in CHCl3/MeOH were
dried under a continuous stream of nitrogen at room temperature. The
resulting lipid/peptide film was rehydrated by adding the appropriate
buffer, vortexing, and incubating at 55°C for 15 min. The multilamellar
vesicles thus formed were sonicated for 2  1 min at 55°C with a 10-s
interval. The vesicles were cooled to 37°C and used immediately.
Lipid mixing
Lipid mixing experiments were performed as described by Oosterlaken-
Dijksterhuis (Oosterlaken-Dijksterhuis et al., 1992). Phospholipid SUVs
(300 nmol of lipid) with or without peptides were mixed with pyrene-PC-
labeled SUVs (15 nmol of lipid containing 10% pyrene-PC) in a HEPES
buffer (25 mM, pH 7.0) supplemented with 0.2 mM EGTA at a final
volume of 2 ml. A standard concentration of 0.4 mol% was used for the
two peptides and hSP-B, and an additional experiment with a twofold
concentration for SP-B1–25 was performed. Fluorescence emission spectra
were recorded before and after the addition of 30 l 0.3M CaCl2 on a
Perkin-Elmer LS 50 fluorescence spectrophotometer. The excitation wave-
length was 343 nm, and the emission between 360 and 550 nm was
recorded. The excimer/monomer (E/M) ratio, indicative of the amount of
lipid mixing, was calculated by dividing the intensity at 475 nm (excimer
fluorescence) by the intensity at 377 nm (monomer fluorescence).
Captive bubble surfactometry
The activity of the synthetic SP-B analogs in inserting lipids into the
air/liquid interface was determined using a pressure-driven captive bubble
surfactometer (Putz et al., 1994). A bubble (0.5 cm2) was formed in
subphase buffer (140 mM NaCl, 10 mM HEPES, 0.5 mM EDTA, 2.5 mM
CaCl2, pH 6.9) by injecting air (28.5 l) into the sample chamber at 1.0 bar
and 37°C. Two methods of surface film formation were used, i.e., film
spreading and adsorption from the subphase.
Film spreading
Stock solutions of DPPC:POPG with a molar composition of 8:2 with or
without proteins were prepared in CHCl3:MeOH (1:1, v/v). From this stock
solution 0.05 l (0.25 nmol lipids) was spread at the air/water interface
with a glass syringe. The subphase was stirred for 60 min to enhance the
desorption of solvent, after which the sample chamber was perfused for 30
min with 7 ml buffer. Subsequently, 50 l SUV (DPPC:POPG, 80:20
mol/mol) was injected into the subphase (final concentration 200 g
PL/ml), and stirring was continued for another 15 min. The bubble area
was increased by sudden lowering of the pressure to 0.5 bar for 10 s.
Subsequently, the bubble was cycled five times between two preset pres-
sure values of 0.5 and 2.8 bar in 1 min, resulting in a dynamic compression
and expansion of the air bubble. After the cycling procedure, another
15-min adsorption time was allowed, followed by a second series of five
cycles. A video camera continuously monitored the shape of the bubble,
from which the surface tension values were calculated (Putz et al., 1998).
Film adsorption
SUVs of DPPC: POPG (8:2, mol/mol) or DPPC:POPG:PA (7:2:1) with or
without proteins were prepared as described and injected directly into the
sample chamber. The final concentration in the subphase was 200 g
lipids/ml. The material was allowed to adsorb to the interface of the bubble
for 15 min, followed by the same cycling and readsorption period described
above. The extra adsorption period between the cycle series was introduced
after pilot experiments with the peptides. These revealed that new material
could be adsorbed from the subphase to the monolayer after the first
cycling series to give rise to lower starting surface tensions at 1 bar for the
second series and lower surface tensions during cycling.
RESULTS
Lipid mixing
The peptides SP-B1–25 and dSP-B1–25 were tested for their
activity to induce lipid mixing. When donor vesicles con-
taining pyrene-PC are mixed with acceptor vesicles (initi-
ated by the addition of calcium ions), the fluorescent lipid
probe becomes diluted, leading to more monomeric fluores-
cence and less excimeric fluorescence. The results are de-
picted in Fig. 3; they show that both SP-B-based peptides
have an activity comparable to that of hSP-B. SP-B1–25 has
a slightly lower activity based on molar concentrations, but
doubling the amount of SP-B1–25 (to achieve the same
amount of protein by weight compared to dSP-B1–25) di-
minishes this difference.
Captive bubble surfactometry
Adsorption
With the captive bubble surfactometer, several aspects of
surface film formation and dynamics can be investigated.
The adsorption of material from vesicles in the subphase to
FIGURE 3 Effect of SP-B analogs on lipid mixing. Black bars represent
the E/M ratio before and white bars the E/M ratio after calcium addition.
2 SP-B1–25 has a twofold increased peptide concentration (0.8%) com-
pared to dSP-B1–25 and hSP-B. Values shown are the average of at least
four separate experiments  SEM.
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a clean interface of the air bubble in the cuvette is easily
detected by a change in the shape of the bubble during the
adsorption period. Lipid SUVs containing the synthetic
peptides or control vesicles were injected into the cuvette
and allowed to adsorb for 15 min. No significant change in
surface tension was detected after this time period. The final
surface tensions are depicted in Table 1. Using DPPC:
POPG (8:2, mol/mol) vesicles, we found that the SP-B
analogs show a clear activity compared to protein-free sam-
ples (40 and 43 mN/m versus 53 mN/m for the protein-free
sample). However, the values are significantly higher than
the values for hSP-B or hSP-C (23 and 28 mN/m). Increas-
ing the protein concentration to 3 mol% did not induce an
increased adsorption, showing that the amount of protein is
not the limiting factor in this process. Using DPPC:
POPG:PA (7:2:1) vesicles also did not affect the adsorption
kinetics of either of the synthetic analogs or of hSP-B,
although slightly lower surface tension values and a ten-
dency toward concentration dependence were observed for
SP-B1–25.
Cycling of adsorbed films
DPPC:POPG vesicles
The maximum and minimum surface tensions (max and
min) during cycling with the DPPC:POPG mixture are
shown in Fig. 4. Both SP-B1–25 and dSP-B1–25 show in-
creased activity compared to protein-free samples, with a
10th-cycle max value of 57 mN/m for SP-B1–25 and 48
mN/m for dSP-B1–25 (versus 60 mN/m for protein-free
vesicles), while the min values are 12 mN/m (versus 20
mN/m for the protein-free sample). However, the peptides
are significantly less active than hSP-B or hSP-C (not
shown). These proteins reach near-zero surface tensions
upon the first (hSP-B) or the sixth cycle (hSP-C, the first
cycle after the extra adsorption period). The maximum
values are also significantly lower for the native proteins
than those for the peptides. Increasing the peptide concen-
tration to 3 mol% gave rise to some improvement for both
SP-B1–25 and dSP-B1–25, but they were still not comparable
to the native protein (results not shown). Interestingly, the
dimer peptide always shows better activity than the mono-
mer peptide. Even when 3% SP-B1–25 is compared to 1%
dSP-B1–25 (which also means on a weight basis more mono-
mer peptide), the dimer has significantly lower max values.
DPPC:POPG:PA vesicles
The addition of PA to the lipid mixture gave rise to dramatic
effects, especially on the minimum surface tensions (Fig.
5 A). One percent dSP-B1–25 reached near-zero min values
upon the first cycle, comparable to hSP-B (result not
shown), while the max value (42.5 mN/m for the 10th
cycle) is also significantly lower compared to the PA-free
experiments. The same effect is observed for the monomer,
but only at higher concentrations (Fig. 5 B). The 2% SP-B1–25
sample reached near-zero min values with the sixth cycle,
while 3% SP-B1–25 was completely comparable to 1%
dSP-B1–25. In contrast to the peptide samples, no effect of
PA was observed when hSP-B was used. Furthermore,
when as little as 0.02% SP-B (which is below the optimum
SP-B concentration) was incorporated into the SUVs, equal
max and min values were detected with or without PA
(results not shown).
Spread films
The advantage of spread films over adsorbed films is that, at
the start of the experiment, the exact composition of the
surface film is known. Lipids (0.25 nmol) with or without
peptide were spread at the air/liquid interface, and cycling
was performed as described in the experimental procedures.
Fig. 6 shows that SP-B1–25 at a concentration of 2% reaches
a near-zero surface tension upon the first cycle, which then
steadily increases with each cycle. This is interpreted as
irreversible loss of material during compression of the bub-
ble (especially when the bubble is compressed beyond the
point where minimal surface tension is reached—overcom-
TABLE 1 Surface tensions (in mN/m) after 15-min
adsorption of peptide-containing vesicles
Mol% peptide DPPC:POPG vesicles DPPC:POPG:PA vesicles
None 53.2  2.6 53.1  3.9
3% hSP-C 27.9  2.5 Not done
1% hSP-B 22.6  0.34 24.9  2.0
1% SP-B1–25 40.6  1.5 42.8  1.6
2% SP-B1–25 41.1  1.0 40.6  1.8
3% SP-B1–25 42.5  0.9 37.1  2.3
1% dSP-B1–25 36.3  0.4 40.2  0.9
3% dSP-B1–25 38.3  1.4 Not done
FIGURE 4 Maximum and minimum surface tensions during cycling of
adsorbed films from DPPC:POPG (8:2) SUV. Two hundred micrograms of
SUVs was injected into the subphase and allowed to adsorb to the interface
for 15 min. Then cycling was performed by varying the pressure between
0.5 and 2.8 bar. The values shown are the average of at least three separate
experiments  SEM.
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pression). A similar behavior for the protein-free lipid sam-
ple is seen, in contrast to a stable min value throughout the
whole cycling procedure for 1% dSP-B1–25 and native
SP-B.
The max values of the dSP-B1–25 sample are also signif-
icantly lower than that of 1% (results not shown) or 2%
SP-B1–25 and reach values close to native SP-B values (59,
46, and 40 mN/m for SP-B1–25, dSP-B1–25, and hSP-B,
respectively). The increasing max values upon cycling for
SP-B1–25 are not observed after the second cycle for native
SP-B and dSP-B1–25.
Refinement of the surface film
Surface tension-area isotherms show valuable information
on refinement of the monolayer upon cycling. A represen-
tative curve is shown in Fig. 7 A for 1% dSP-B1–25 (using
adsorbed films from DPPC:POPG:PA vesicles) and 0.02%
hSP-B (Fig. 7 B). This figure shows that the dSP-B1–25 film
requires less area reduction on consecutive cycles to reach
low surface tensions and that dSP-B1–25 surface films re-
quire larger reductions to reach these low tensions than
hSP-B films. However, because each cycle starts from a
FIGURE 7 Representative surface tension-area isotherms of adsorbed
films of 1% dSP-B1–25 (A) and 0.02% hSP-B (B).
FIGURE 5 Maximum and minimum surface tensions during cycling of
adsorbed films from DPPC:POPG:PA (7:2:1) SUV. Two hundred micro-
grams of SUVs was injected into the subphase and allowed to adsorb to the
interface for 15 min. Then cycling was performed by varying the pressure
between 0.5 and 2.8 bar. The values shown are the average of at least three
separate experiments  SEM.
FIGURE 6 Maximum and minimum surface tensions during cycling of
spread films of DPPC:POPG (8:2). Peptide/lipid mixtures were dissolved
in CHCl3/MeOH. Lipids (0.25 nmol) in 0.05 l were spread at the
interface. The subphase was washed, and vesicles without peptides were
injected into the subphase. Then cycling was performed by varying the
pressure between 0.5 and 2.8 bar. The values shown are the average of at
least three separate experiments  SEM.
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different max (with significantly lower values for hSP-B),
they cannot be compared directly. Therefore, the area re-
ductions needed to reach surface tensions of2 mN/m from
20 mN/m were calculated. For the dSP-B1–25 samples these
reductions fell from 34.3 1.5% in the first cycle to 26.4
0.6% and 19.1  2.7% in the second and fourth cycles,
respectively. This indicates that the monolayer is enriched
in DPPC during the cycling procedure. The isotherms of
SP-B1–25 were comparable (when 3% SP-B1–25 was used) to
the one shown for dSP-B1–25. The calculated area reductions
needed for the decrease from 20 to 2 mN/m were 37.2 
4.5%, 26  3.5%, and 25  3.1% for the first, second, and
fourth cycles. Fig. 7 B shows a typical surface tension-area
isotherm of 0.02% hSP-B. The decrease in area reduction
required to reach 2 mN/m upon cycling is almost absent in
this experiment. The calculated values are 24 3.6%, 19
4.3%, and 19  5.6% for the first, second, and fourth
cycles, respectively.
DISCUSSION
In this paper the in vitro surface activity of two synthetic
SP-B analogs, based on the N-terminal segment of human
SP-B, was tested. The monomeric SP-B1–25 shows a clear
activity compared to nonprotein samples. dSP-B1–25, the
dimeric peptide, shows an even better activity in some
aspects of surface film dynamics, especially respreadability
of lipids, which resembles the native protein activity.
The lipid mixing activities of dSP-B1–25 and SP-B1–25
were found to be similar to native SP-B (Fig. 3). The
fusogenic properties are thought to be important in surfac-
tant function in several aspects. They likely play a role in
forming contact points between the lipid monolayer at the
air/liquid interface and the bilayer structures that are at-
tached to it. This enables the lung to insert new material into
the interface when the surface is enlarged (during inspira-
tion) to maintain a relatively low surface tension. Fusogenic
events are also thought to be important in the formation of
tubular myelin, which contains highly curved structures at
the edges of the tubules where lipid bilayers merge.
The adsorption of lipids to a clean air/liquid interface
from vesicles in the subphase was clearly stimulated by the
presence of SP-B1–25 or dSP-B1–25. However, the values
obtained were, in all of the experiments performed, 15
mN/m or more above the observed equilibrium surface
tension of 23 mN/m (Table 1). This indicates that the
peptides cannot penetrate an existing, relatively tightly
packed monolayer with a surface tension of 35 mN/m and
fuse with it. These results are in line with results that were
obtained for SP-B1–25 with a Langmuir-Wilhelmy balance
(Bruni et al., 1991). In those experiments it was observed
that if lipid films were spread to an initial surface pressure
of42 mN/m (surface tension of 30 mN/m), no insertion of
peptide could occur. However, in our experiments it was
observed that “extra” adsorption can occur despite the ex-
isting monolayer after the first cycling series. Somehow,
because of the cycling procedure, new material from pep-
tide-containing vesicles was now capable of inserting into
the interface. A possible explanation for this phenomenon is
that cycling has induced a lipid reservoir, probably consist-
ing of lipid bilayer structures in close contact with the
monolayer at the interface. The contact points between the
monolayer and the reservoir would then allow an easy
adsorption of new lipids into the interface, despite the
relatively low surface tension of 40 mN/m, which pre-
vents adsorption from “normal” subphase vesicles.
The cycling experiments with spread films show that
dSP-B1–25 films but not SP-B1–25 give rise to stable, near-
zero min during the whole cycling procedure. This shows
that the material that is squeezed out during compression
stays attached to the monolayer and is directly available for
reinsertion upon the next expansion. Insertion of new lipids
from the subphase vesicles occurs at a much slower rate and
will therefore only play a minor role during the dynamic
cycling. The easiest explanation for the observed difference
is that dSP-B1–25 can form a bridge between the monolayer
and the squeezed-out subphase lipids by attaching one
monomer part to each membrane structure. SP-B1–25 does
not offer this possibility, and loss of material is observed
through rising max and min values upon cycling. The
major role of the dimerization of native SP-B is thought to
be this bridging function. The results obtained in this study
strongly support this theory.
Recently, the requirement of SP-B dimerization for opti-
mal activity was demonstrated in a mouse animal model
(Beck et al., 2000). These mice expressed a monomeric
SP-B mutant in an SP-B / background. Large aggregate
surfactant from bronchoalveolar lavage and purified SP-B
monomer or dimer, reconstituted with lipids, was tested and
revealed slower adsorption kinetics and higher min values
during cycling experiments. Although we did not find im-
proved adsorption for dSP-B1–25 compared to SP-B1–25,
these results strongly support our findings.
Contrary to the results presented here, the monomeric
SP-B1–25 has been shown in monolayer studies to be able to
create a reservoir of squeezed-out lipids that can reenter
upon expansion (Lipp et al., 1997, 1998). This discrepancy
is probably due to the dynamic system that was used in the
current experiments. The differences observed for the pro-
tein-free sample with former captive bubble studies (Putz et
al., 1999; Veldhuizen et al., 1999) in which the protein-free
sample also creates low min values during the whole cy-
cling procedure are probably due to the lower lipid subphase
concentration in our current experiments. Similar rising
min values are observed when no lipid vesicles are injected
into the subphase (unpublished results).
A dramatic effect of PA on the peptides’ activity was
observed (Fig. 4 and 5). In contrast to the results with
DPPC:POPG vesicles, near-zero surface tensions upon the
first cycle were observed when PA was included in the
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vesicles. In other words, PA somehow enhances the creation
of a DPPC-enriched monolayer upon compression. We pro-
pose that the presence of PA induces a specific squeeze-out
of non-DPPC lipids during compression. DPPC-poor do-
mains within the monolayer could be more easily formed,
which are then squeezed out upon compression of the bub-
ble, leading to an almost pure DPPC monolayer at the
interface. Following this theory, the adsorbed films from
DPPC:POPG vesicles would contain enough DPPC to reach
very low surface tensions, but fail to do so because DPPC is
squeezed out together with POPG when the bubble is com-
pressed. Interestingly, the advantageous effect of PA was
not observed when hSP-B was used in adsorbed films
(results not shown). The effect could therefore be specific to
the combination with the peptides, or the advantageous
effect of PA could be more subtle with hSP-B and only
show up at lower concentrations of SP-B or in a different
experimental setup.
The surface tension-area isotherms show that upon cy-
cling increasingly less surface area reduction is needed to
reach a very low surface tension (Fig. 7). This reflects an
enrichment in DPPC of the monolayer. The area reduction
required to reach very low surface tensions decreased sig-
nificantly for both peptides upon cycling. A pure DPPC
monolayer requires 15% area reduction to reach this value
from equilibrium surface tension (Schu¨rch et al., 1989,
1992), which is close to the value obtained for the SP-B1–25
and dSP-B1–25 films after a few cycles. The hSP-B sample
showed a smaller effect in these decreasing values but
started already with a relatively small required area reduc-
tion upon the first cycle. This implies that the monolayer
was already enriched in DPPC during the initial adsorption
period. This has been observed before, using the natural
surfactant BLES (Schu¨rch et al., 1992). In these experi-
ments a fast adsorption of the material was always accom-
panied by lower area reductions needed to reach near-zero
surface tensions. In other words, a fast adsorption results in
a specific DPPC enrichment of the monolayer. The adsorp-
tion of SP-B1–25 and dSP-B1–25 in our experiments was slow
(and that of hSP-B fast), and following this line of thought,
no specific DPPC adsorption has occurred. This indicates
that, with the synthetic peptides, the surface film is mostly
enriched in DPPC because of selective squeeze-out of the
non-DPPC lipids.
In summary, two peptides based on the N-terminal seg-
ment of SP-B have been tested. Both peptides contain many
characteristics of the native protein in lipid mixing and
captive bubble surfactometer experiments. The dimeric pep-
tide has a clearly increased activity compared to the mono-
meric peptide in reservoir formation upon cycling. We
presume that dimerization is required to create a lipid res-
ervoir in close contact with the lipid monolayer at the
interface and that dimerization of native SP-B has a similar
function.
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